T-Cell Immunotherapy Market, 2030: Post the Early Success

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
118
T-Cell Immunotherapy Market, 2030: Post the Early Success of Immune Checkpoint Inhibitors, T-Cell Immunotherapy has Emerged as Another Innovative and Potent Arm of this Market

Dublin, Feb. 14, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "T-Cell Immunotherapy Market (2nd Edition), 2017-2030" report to their offering. The "T-Cell Immunotherapy Market, 2017-2030 (2nd edition)" report features an extensive study of the current market landscape and the future potential of T-cell immunotherapies. Immuno-oncology has been gradually nurtured by researchers over the last several years and is now considered as the fourth major pillar of cancer therapy, after surgery, chemotherapy and radiotherapy. As indicated earlier, the T-cell therapy market has evolved significantly over the last few years, offering promising opportunities for a variety of stakeholders. The domain is characterized by a robust and opportunistic pipeline of product candidates focused on targeting hematological cancers and solid tumors. However, with no marketed products, this emerging field is still in its infancy. The report provides a comprehensive overview of the market, focusing particularly on CAR-T therapies, TCR therapies and TIL therapies. The role of academic players/research institutes has been critical in this domain. Post the establishment of initial proof-of-concept, several industry players have entered into collaboration with non-industry participants to fund the clinical and commercial development of potential product candidates. Some late stage products that have emerged out of such collaborations include CTL-019 (Novartis/University of Pennsylvania), KTE-C19 and HPV-16 E6 TCR (Kite Pharma/National Cancer Institute), and LN-144 (Lion Biotechnologies/National Cancer Institute). As mentioned before, encouraging clinical results have significantly accelerated the progress of these therapies. Several technology providers, especially those with capabilities in genome editing, and viral and non-viral gene transfer, are also actively involved in this emerging market. Many of these players have entered into partnerships with therapy developers in order to assist in designing novel features to enhance the efficacy and potency of existing T-cell therapies. A prominent example of such a technology is safety switches; these are innovative molecular tools designed to manage known side effects, such as cytokine release syndrome and B-cell aplasia, by allowing control over the expression of certain genes in the engineered cell population. One of the key objectives of the study was to review and quantify the future opportunities associated with the ongoing programs of both small and big pharmaceutical firms in this domain. It is worth mentioning that there is a lot of hope pinned on multiple start-ups, which have received significant backing by several strategic investors and venture capital firms. Key Topics Covered: 1. Preface 2. Executive Summary 3. Introduction 4. Market Landscape 5. Chimeric Antigen Receptor-T (CAR-T) Cell Therapy 6. T-Cell Receptor (TCR) Based Therapies 7. Tumor Infiltrating Lymphocytes (TIL) Based Therapies 8. Market Opportunity 9. Key Therapeutic Areas for T-Cell Therapies 10. Emerging Technologies 11. Social Media: Emerging Trends 12. Partnerships and Collaborations 13. Venture Capital Support 14. Other T-Cell Immunotherapies 15. Case Study: Cell Therapy Manufacturing 16. T-Cell Immunotherapy: Cost Price Analysis 17. Company Profiles 18. Interview Transcripts 19. Conclusion 20. Appendix 1: Tabulated Data 21. Appendix 2: List of Companies and Organizations - AGF Private Equity - AJU IB Investment - ARCH Venture Partners - AURORA BioPharma - AVG Ventures - AbVitro - AbbVie - Abingworth - AbraxisBioScience - Adaptimmune - Adicet Bio - Advanced BioScience Laboratories - Adverum Biotechnologies - Affiliated Hospital to Academy of Military Medical Sciences - AgonOx - Agreen Biotech - Alaska Permanent Fund - Albert Einstein College of Medicine - Alexandria Ventures - Alexion Pharmaceuticals - Allen Laboratories - Allos Therapeutics - Alpine Immune Sciences - Alta Partners - AltorBioScience - Amgen - Amsterdam BioTherapeutics Unit - Antoni van Leeuwenhoek Hospital - ApcethBiopharma - Aquilo Capital Management - Argos Therapeutics - ArtaxBioPharma - Astellas Pharma - AstraZeneca - Asymptote - Atara Biotherapeutics - Atlantic Bio GMP - Atlas Venture - Atreca Therapeutics - Autolus - Avidex - BankInvest Biomedical Venture - Batavia Biosciences - Bavarian Nordic - Baxalta - Bayer - Bayer Crop Sciences - Baylor College of Medicine - Beijing Doing Biomedical - Bellicum Pharmaceuticals - Bezos Expeditions - Bill & Melinda Gates Foundation - Bio Elpida - BioLife Solutions - BioNTech - BioVeda China Fund - Biogen - Biomedical Catalyst - Biomedical Catalyst Fund - Biotecnol - Bluebird bio - Boehringer Ingelheim - Boston Children's Hospital - Bpifrance - Brace Pharma Capital - Breast International Group - Bristol-Myers Squibb - Broad Institute - Broadfin Capital - CARsgen Therapeutics - CELLforCURE - CHDI Foundation - CRISPR Therapeutics - Cabaret Biotech - Caladrius Biosciences - California Institute for Regenerative Medicine - Cancer Prevention and Research Institute of Texas - Cancer Research UK - Cardiff University - Caribou Biosciences - Cartherics - Casdin Capital - Celgene - Cell Design Labs - Cell Medica - Cell Therapies - Cell Therapy and Cell Engineering Facility - Cell and Gene Therapy Catapult - Cellectis - Cellular Biomedicine Group - Cellular Therapeutics - Celyad - Centre for Cell Manufacturing Ireland - Changzheng Hospital - Charité - Universitätsmedizin Berlin - Chengdu MedGenCell - Children's Hospital of Philadelphia - Children's Mercy Hospital Kansas City - Chimeric Therapeutics - Chinese PLA General Hospital - Christie NHS Foundation Trust - Chugai Seiyaku Kabushiki Kaisha - City of Hope Medical Center - Clough Capital Partners - Cognate Bioservices - Cold Genesys - Columbia University - Cooperative Research Center for Cell Therapy Manufacturing - Corixa - Cowen Group Investment - Cystic Fibrosis Foundation Therapeutics - Cytolumina Technologies - Cytovance Biologics - Dana-Farber Cancer Institute - Dangdai International - Dartmouth College - Deerfield Management - Delenex Therapeutics - Dendreon - Duke University - Dutch Cancer Society - ERS Genomics - EUFETS - Easton Capital - EcoR1 Capital - Editas Medicine - Edmond Venture Capital - Eisai - Eli Lilly - Endocyte - Erasmus University Medical Center - Eureka Therapeutics - FCB-Pharmicell - FGP Capital - Fate Therapeutics - Fetolumina Technologies - Fidelity Biosciences - Fidelity Management & Research Company - Financière IDAT - Finnish Innovation Fund - Five Prime Therapeutics - Flagship Ventures - Fondazione Telethon - Forbion Capital Partners - Foresite Capital - Formula Pharmaceuticals - Fortress Biotech - Franklin Templeton Investments - FraunhoferInsitute for Cell Therapy and Immunology - Fred Hutchinson Cancer Research Center - Fuda Cancer Hospital - GE Global Research - Gadeta - GammaCell Bio-Technologies - Gene and Cell Therapy Lab - Genentech - GigaGen - Gilead Sciences - GlaxoSmithKline - Google Ventures - Great Ormond Street Hospital - Green Cross Cell - Griffin Securities - Guy's and St Thomas' NHS Foundation Trust - Généthon - H. Lee Moffitt Cancer Center and Research Institute Hospital - Hadassah Medical Organization - Harvard University - Heat Biologics - Herlev Hospital - Howard Hughes Medical Institute - iCarTABBioMed - iCell Therapeutics - ImClone Systems - Immatics - Immune Therapeutics - Immunex - ImmunoCellular Therapeutics - Immunocore - Immunovative Therapies - Imperial College London - Imperial Innovations - Innovative Cellular Therapeutics - Innovative Genome Initiative - Institut Curie (Curie Institute) - Institut Pasteur (Pasteur Institute) - Institute of Translational Health Sciences - Intellia Therapeutics - Intrexon - Iowa State University - JCR Pharmaceutical - JIC GenesisFountain Healthcare Ventures - JMP Securities - JW Biotechnology - Janssen Biotech - Janus Capital Group - Jennison Associates - Jichi Medical University Hospital - John Wayne Cancer Institute - Johns Hopkins Kimmel Cancer Center - Johns Hopkins University - Johnson & Johnson - Jolly Innovation Ventures - Juno Therapeutics - KTB Ventures - Kaitai Capital - Karolinska University Hospital - Keio University School of Medicine - Khosla Ventures - King's College London- Rayne Cell Therapy Suite - Kite Pharma - Leiden University Medical Center - Leucid Bio - Lifeline Ventures Fund - Ligand Pharmaceuticals - Lilly Asia Ventures - Lion Biotechnologies - Lion TCR - Lonza Biologics - Loyola University - Lymphoma and Leukemia Society - MD Anderson Cancer Center - MaSTherCell - MabQuest - Malin Corporation - Massachusetts General Hospital - Max DelbrückCenter for Molecular Medicine - MaxCyte - Mayo Clinic - MedImmune - MedPost Urgent Care - Medarex - Medicxi Ventures - Medigene - Memorial Sloan Kettering Cancer Center - Merck - Merck Serono - Merlin Nexus - Mie University - Millennium Pharmaceuticals - MiltenyiBiotec - Mission Bay Capital - MolMed - Molecular and Cellular Therapeutics - Morphotek - Mustang Bio - NIHR Oxford Biomedical Research Centre - NantKwest (earlier Conkwest) - NantWorks - Nantes University Hospital - National Cancer Institute - National Institute of Allergy and Infectious Diseases - National Institutes of Health - National University of Ireland - National University of Singapore - Netherlands Cancer Institute - New Enterprise Associates - New Leaf Venture Partners - New River Management - NewVa Capital Partners - Novartis - Novartis Venture Fund - Novo Ventures - ODYSSEE Venture - ONO Pharmaceutical - OSEO - Oberland Capital - Ohio State University - Omega Funds - OnCyte - Oncodesign Biotechnology - Onyx Pharmaceuticals - Opexa Therapeutics - Opus Bio - OrbiMed - Ospedale San Raffaele (San Raffaele Hospital) - OspedalePediatrico Bambino Gesù (Bambino Gesù Children's Hospital) - Oxford BioMedica - PLA General Hospital - Partners Innovation Fund - Peking University - Perceptive Bioscience Investments - PersonGen Biomedicine (Suzhou) - Peter MacCallum Cancer Centre - Pfizer - PharmaCell - Pharmacyclics - Pierre Fabre Group - Polaris Partners - PolyBioCept - Pontifax - Poseida Therapeutics - Precision BioSciences - Pregenen - Progenitor Cell Therapy - Prometheus Laboratories - QVT Financial - QueensBridge Venture Partners - Quogue Capital - RA Capital Management - Ramius Capital Group - Redmile Group - RedoxTherapies - Regeneron Pharmaceuticals - Remeditex Ventures - Renji Hospital - Ridgeback Capital Management - Ridgeway Capital Partners - Riverbank Capital Securities - Roche - Rock Springs Capital - Rockland Immunochemicals - Roger Williams Medical Center - Roswell Park Cancer Institute - Royal Adelaide Hospital Cancer Center - SOLTI Breast Cancer Research Group - SOTIO - SR One - Sabby Management - Sanford Research - SangamoBioSciences - Sanofi Aventis - Sanofi-Genzyme BioVentures - Schering-Plough - Scottish National Blood Transfusion Service (SNBTS) Cellular Therapy Facility - Seattle Children's Hospital - Seattle Genetics - Second Affiliated Hospital of Henan University of Traditional Chinese Medicine - Second Military Medical University - Sectoral Asset Management - Servier - Shanghai Cancer Institute - Shanghai Chest Hospital - Shanghai Genechem - Sheba Medical Center - Shenzhen Institute for Innovation and Translational Medicine - Shenzhen Second People's Hospital - Shionogi - Sichuan University - Sidney Kimmel Comprehensive Cancer Center - Sinobioway Cell Therapy - Sorrento Therapeutics - Southwest Hospital - Spectrum Pharmaceuticals - St. Jude Children's Research Hospital - Stage Cell Therapeutics - Stanford University - Stifel - Sun Yat-Sen University - Super-T Cell Cancer Company - Syncona - T-Cell Factory - T. Rowe Price Associates - TILT Biotherapeutics - TNK Therapeutics - TRACT Therapeutics - TVAX Biomedical - TVM Capital - Takara Biosciences - Targazyme - Techno Venture Management - Tel Aviv Sourasky Medical Center - Terumo - Tessa Therapeutics - Tethys Holdings - Texas Emerging Technology Fund - The Clinical Cell and Vaccine Production Facility - Theravectys - Thermo Fisher Scientific - Third Military Medical University - Third Rock Ventures - Third Security - Three Arch Opportunity Fund - TiGenix - Tianjin Medical University Cancer Institute and Hospital - Tmunity Therapeutics - Tongji Hospital - Tongji University School of Medicine - Transposagen Biopharmaceuticals - TriumviraImmunologics - Two Blades Foundation - TxCell - UCLA Jonsson Comprehensive Cancer Center - UNC Lineberger Comprehensive Cancer Center - United Therapeutics - UniQure - Universal Cells - University College London - University Health Network, Toronto - University Medical Center Utrecht - University of Birmingham - University of California, Berkeley - University of Florida - University of Lausanne - University of Milano-Bicocca - University of Minnesota - University of Oxford - University of Pennsylvania - University of Zurich - Unum Therapeutics - Uppsala University - Utrecht Holdings - VGXI - Vaccinogen - Valeant Pharmaceuticals - VenBio - Venrock - Versant Ventures - Vertex - Vical - Viking Global Investors - ViroMed - VorBiopharma - Weill Cornell Graduate School of Medical Sciences - Wellington Management - West China Hospital - Woodford Investment Management - WuXiAppTec - Wunderlich - Wyeth (Pfizer) - X-Body - Xijing Hospital - Xinqiao Hospital - Xuzhou Medical College - ZIOPHARM Oncology - Zhujiang Hospital

For more information about this report visit http://www.researchandmarkets.com/research/9dft7v/tcell

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Oncology Drugs

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Nevada Expands Rural Youth Mental Health Access

Updated Category News Views 171

Nevada's Rural Mental Health Crisis When you're navigating the barren stretches of rural Nevada, the scenic views can be breathtaking. But for many families, finding basic services like mental health care is as challenging as striking water in the desert. Cartwheel Care has taken the bull by the horns with their latest initiative to bridge this glaring gap. Partnering...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 90

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 25

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
AR Cards in Casino Gaming: A High-Stakes Revolution

Updated Category News Views 31

A New Breed of Casino Experience Walk into a casino today, and you might just enter a whole new reality. No, this isn’t a cheesy magician’s trick or a glitzy PR stunt—this is the real deal brought to you by augmented reality (AR) trading cards. Imagine the slots you love wrapped in a sci-fi movie where characters leap out, tap you on the shoulder, and call you by...

Continue Reading
Biel Crystal Solidifies Position as Key iPhone UTG Supplier

Updated Category News Views 95

Biel Crystal Hones In On Foldable iPhone Tech Here's the lowdown: Apple's making waves with their first foldable phone, the iPhone Duo, and Biel Crystal? They're the rockstars cranking out that ultra-thin glass making it all possible. You might not have heard their name tossed around as much, but they're heavy hitters in the tech components scene. Biel Crystal's been...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 124

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 234

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 39

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Paris Baguette Expands U.S. Presence with New Georgia Café

Updated Category News Views 148

Café Culture Meets Expansion Chase You ever sip a cup of coffee and hear the rustle of opportunity in the steam? That's what's brewing at Paris Baguette with their new opening in Peachtree Corners, Georgia. This isn't just another café setting up shop; it's part of a larger scheme—expanding their sweet slice of the global market pie. Paris Baguette's Georgia Gamble...

Continue Reading
Ranger and Smith Unveil Tea-Infused Chocolate Bar

Updated Category News Views 63

Fresh Collaborations in Portland's Culinary Scene Ah, the sweet crossover in Portland's food scene is once again in the spotlight with a new entry that's sure to titillate taste buds. Ranger Chocolate Co. and Steven Smith Teamaker are at it again, rolling out a delectable creation that merges the poetic elegance of tea with the indulgent richness of chocolate. Welcome,...

Continue Reading

Top 5 Most Recently Viewed Articles

Algeness® VL Filler Receives Marketing Approval in China

Updated Category News Views 273

Exciting Developments for Advanced Aesthetic Technologies Advanced Aesthetic Technologies, Inc. (AAT) recently celebrated a significant milestone with the approval of their Algeness® VL agarose facial injection filler for marketing in China. This landmark achievement opens up new avenues for AAT in expanding their product offerings in the Asian market and showcases their...

Continue Reading
Criminal Charges Anticipated in Trump Campaign Hacking Case

Updated Category News Views 154

Criminal Charges Expected in Trump Campaign Hacking Case U.S. authorities are preparing to file criminal charges regarding an incident in which the Trump campaign claimed its internal communications were hacked, allegedly by the Iranian government. This concerning situation has drawn the attention of both the public and officials, raising serious issues surrounding...

Continue Reading
Semler Scientific Faces Class Action Lawsuit: What Investors Need to Know

Updated Category News Views 187

Semler Scientific and the Class Action Lawsuit Overview In recent news, a class action lawsuit has taken center stage involving Semler Scientific, Inc. (SMLR). Investors who have experienced losses related to their investments in Semler are advised to take note of this development, which may directly impact their financial outcomes. Understanding the Lawsuit This class...

Continue Reading
FTC Solar Engages Investors at Key Industry Conferences

Updated Category News Views 159

FTC Solar Engages Investors at Key Industry Conferences FTC Solar, Inc. (Nasdaq: FTCI), an innovative leader in solar tracker systems and engineering services, is set to make significant strides in connecting with investors at three prominent conferences. These events provide a platform for the management team, including CEO Yann Brandt, to engage in discussions that...

Continue Reading
Anixa Biosciences Set to Share Innovations in Cancer Therapy

Updated Category News Views 88

Anixa Biosciences Set to Conduct a Notable Presentation Anixa Biosciences, Inc. (NASDAQ: ANIX), a leading biotechnology firm dedicated to the treatment and prevention of cancer, has taken a significant step forward by announcing its participation in a prestigious investment conference. This event, the H.C. Wainwright 27th Annual Global Investment Conference, promises to...

Continue Reading